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Abstract: The 22q13.3 deletion, or Phelan-McDermid syndrome, is characterized by global 
intellectual disability, generalized hypotonia, severely delayed or absent speech associated 
with features of autism spectrum disorder, and minor dysmorphisms. Its behavioral phenotype 
comprises sleep disturbances, communication deficits, and motor perseverations. Data on 
psychological dysfunctions are so far not available. Previous studies have suggested that the 
loss of one copy of the gene SH3 and multiple ankyrin repeat domains 3 (SHANK3) is related 
to the neurobehavioral phenotype. Additional genes proximal to SHANK3 are also likely to play 
a role in the phenotype of patients with larger deletions. The present paper describes two adult 
brothers with an identical 2.15 Mb 22qter (22q13.32q13.33) deletion, of whom the youngest 
was referred for evaluation of recurrent mood changes. In both patients, magnetic resonance 
imaging of the brain showed hypoplasia of the vermis cerebelli. Extensive clinical examinations 
led to a final diagnosis of atypical bipolar disorder, of which symptoms fully remitted during 
treatment with a mood stabilizer. In the older brother, a similar psychopathological picture 
appeared to be present, although less severe and with a later onset. It is concluded that the 
behavioral phenotype of the 22q13.3 deletion syndrome comprises absent or delayed speech and 
perseverations with associated autistic-like features, whereas its psychopathological phenotype 
comprises an atypical bipolar disorder. The latter may have implications for the treatment regime 
of the syndrome-related behavioral disturbances.
Keywords: 22q13.3 deletion syndrome, 22qter, Phelan-McDermid, SHANK3, autism spectrum, 
unstable mood disorder, cerebellar vermis
Introduction
More than a decade ago, a small number of patients were described in whom a telomeric 
deletion of the chromosomal region 22q13 was present and whose main phenotypical 
characteristics included marked developmental delay and absence of speech.1–3 
Subsequently, the clinical picture of the 22q13 deletion syndrome was systematically 
elaborated by Phelan et al.4 According to their report, this deletion syndrome is charac-
terized by global intellectual disability (ID), childhood hypotonia, severely delayed or 
absent speech, features of autism spectrum disorder (ASD) and normal to accelerated 
growth in the absence of major dysmorphisms and somatic anomalies. Since then, 
the 22q13 deletion syndrome has also been called Phelan-McDermid syndrome 
(OMIM: 606232), and more than 100 cases with deletions of variable length have 
been published.5–7 The exact prevalence is unknown and the syndrome is thought to 
be underdiagnosed. In a large cohort study among 11,000 patients with ID, it was the 
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second most frequent subtelomeric rearrangement, suggest-
ing that it is a relatively common chromosomal disorder.5
The SH3 and multiple ankyrin repeat domains 3 (SHANK3) 
gene that is localized within the common deleted region were 
suggested to be responsible for at least the neurobehavioral 
features, including ID and features of ASD.8,9 This was sup-
ported by the presence of a balanced translocation disrupting 
SHANK3 in a patient with the 22q13 deletion syndrome 
phenotype,10,11 and further confirmed by patients with dele-
tions restricted to SHANK3. The latter is a brain-specific gene 
and has a critical function for the postsynaptic densities in the 
brain. Several previous studies suggested involvement of this 
gene in ASD.12–16 Recently, Sarasua et al7 showed that several 
features of 22q13 deletion syndrome, including hypotonia and 
severity of ID, correspond with the deletion size, suggesting 
that additional genes proximal to SHANK3 contribute to the 
phenotype of these patients as well.
Concerning the behavioral phenotype, several reports 
mention sleep disturbances, communication deficits, and 
behavioral abnormalities such as hyperactivity, restlessness, 
attention problems, repetitive motor activities, and increased 
reactivity to sensory stimuli. Features concerning language 
and social communication are typically subsumed under 
the heading of ASD.12,13,16–19 Apart from the developmental 
aspects mentioned here, data about psychological dysfunc-
tions or psychiatric symptoms are not available as yet.
In an ongoing cohort study among patients with 
 unexplained ID (Department of Human Genetics,  Radboud 
University Nijmegen Medical Centre, Nijmegen, The 
 Netherlands), genome-wide array analysis disclosed a 
2.15 Mb identical 22qter deletion (22q13.32q13.33;  Figure 1) 
in two adult male siblings of whom the youngest was already 
known (first author) with an unstable mood pattern. In the 
absence of any relevant information about psychological 
dysfunctioning in this deletion syndrome, both patients 
were extensively examined in order to identify a possible 
psychopathological phenotype.
Cases
Two male siblings are presented, aged 29 years (Patient 1) 
and 31 years (Patient 2), respectively, both born after uncom-
plicated pregnancies from nonconsanguineous parents. Apart 
from short-lasting episodes of flattened affect in the father, 
family history shows no load with any major psychiatric 
disorder, nor with ID or epilepsy.
Patient 1
The early childhood of this patient was characterized by 
sleep disturbances and a general developmental delay, 
particularly in respect of speech. He frequently displayed 
hyperactive behaviors with temper tantrums. At the age of 
6 years he had a developmental delay of more than 3 years 
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Figure 1 University of California, Santa Cruz genome browser view (GRCh37/hg19) of the deleted region in chromosome 22q13 identified by genome-wide array analysis.
Notes: The red box indicates the chromosomal location schematically depicted. The relative positions of involved genes in the deleted region are shown. The green color 
indicates OMIM disease-causing genes, including SHANK3. Other involved genes are involved in diseases with autosomal recessive inheritance.
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(developmental age 2 years 8 months). Aged 9 years, his 
IQ level corresponded with severe ID. Because of this and 
his recurrent challenging behaviors, the patient had special 
education since the age of 9 years. His medical history 
mentioned only bilateral orchidopexy at the age of 11 years. 
Aged 17 years, marked weight loss occurred and several 
changes in his behavioral repertoire became apparent, in 
that he showed a nearly complete loss of interest in daily 
activities, with marked social withdrawal as well as severe 
anxieties. A provisional diagnosis of major depression was 
made and the patient was treated with fluoxetine. However, 
that had to be stopped after about 6 months because of 
the occurrence of behavioral side effects, particularly 
impulsivities. Two years later, disinhibited behaviors, sleep 
disturbances, and obsessive rituals intensified. Genetic 
analysis at that time showed a normal 46,XY karyotype, and 
Fragile-X syndrome was excluded by FMR1 repeat analysis. 
Again, depression was thought to be the primary cause of 
the behavioral problems and, consequently, treatment with 
citalopram was started, which because of persistent motor 
agitation was replaced some months later by valproic acid in 
combination with haloperidol. Despite maintenance therapy 
with valproic acid (900–1200 mg daily) over a period of 
4 years, he relapsed and was referred to the specialized 
outpatient department of neuropsychiatry.
Psychiatric examination disclosed symptoms of a severe 
major depression with irritability, loss of initiative, and 
marked sleep disturbances. Magnetic resonance imaging 
(MRI) of the brain showed hypoplasia of the cerebellar 
vermis with enlarged cisterna magna, and mild enlargement 
of the lateral ventricles (Figure 2). N europsychological 
assessment revealed severe ID (Vineland screener: 2 years 
4 months) with marked deficits in expressive and receptive 
language. His cognitive profile was dominated by disordered 
attention and executive functioning, specifically expressed in 
hardly uninterruptable perseverative behaviors. Citalopram 
was reintroduced in an increasing dose of 40 mg daily, but 
in the absence of effect was replaced 3 months later by 
nortriptyline (50 mg daily; plasma concentration 176 µg/L). 
Subsequent CYP2D6 genotyping revealed a polymorphism 
(*4/*41; intermediate metabolism) and, based on the plasma 
concentration, the daily dose of nortriptyline was fixed at 
40 mg daily (plasma concentration: 96 µg/L). Valproic acid 
was continued at a stable dose of 1200 mg per day (plasma 
concentration: 58 mg/L). A definite diagnosis of atypical 
bipolar disorder was made (International Classification of 
Diseases-10; F.31.9). Follow-up during a period of 5 years 
showed that his mood and behavior clearly stabilized.
Patient 2
Patient 2 is the older brother. His recent history mentioned 
an unstable pattern of mood and activity with predominant 
recurrent depressive episodes starting at the age of 27 years 
for which he was treated with carbamazepine (400 mg daily; 
4.5 mg/L) and paroxetine (30 mg daily; 39 µg/L) elsewhere. 
Four years later, after establishment of his genetic diagnosis, 
he was referred for extensive neuropsychiatric evaluation, 
which did not disclose any psychopathology. In respect of 
neuropsychology, a developmental age of 3 years 3 months 
(Vineland screener) was established, with a correspond-
ing cognitive profile and communication problems due to 
moderately impaired development of speech and language. 
In particular, deficits in planning and maintaining overview 
were found. MRI of the brain disclosed a similar picture as 
in his younger brother (hypoplasia of the vermis cerebelli 
with enlarged cisterna magna, and mild enlargement of the 
lateral ventricles). Also here, in retrospect, a diagnosis of 
atypical bipolar disorder was made, albeit that relapsing 
symptomatology was less severe and with a later onset. 
Because psychiatric symptoms were in full remission, 
his psychopharmacological treatment regime was kept 
unchanged.
As shown in Table 1, primary behavioral and psycho-
pathological features of both patients are from the mood and 
anxiety domains.
Figure 2 Transversal T2-weighted magnetic resonance imaging of the brain of 
Patient 1, showing hypoplasia of the cerebellar vermis.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
177
Phelan-McDermid syndrome
Neuropsychiatric Disease and Treatment 2012:8
Table 1 Behavioral and psychopathological findings in both 
patients
Patient 1 Patient 2
Intelligence/Adaptation Male/29 Male/31
Vineland screener28 (developmental age in years; months)
 Communication 13 (1;1) 36 (3;0)
 Daily living skills 35 (2;11) 44 (3;8)
 Socialization 28 (2;4) 37 (3;1)
 Motor skills 37 (3;11) 37 (3;1)
 Total score 28 (2;4) 39 (3;3)
Behavior and psychopathology
PIMRA29 (proxy, maximum per scale = 7)
 Schizophrenic disorder 2 1
 Affective disorders 5 4
 Psychosexual disorder 0 0
 Adjustment disorder 3 2
 Anxiety disorders 4 2
 Somatoform disorders 0 0
 Personality disorders 1 0
 Inappropriate mental adjustment 3 1
 PIMRA total score (max = 56) 18 10
Neuropsychiatric rating scale  
(NPI;30 severity [max = 4] × frequency [max = 3])
 Delusions 0 0
 Hallucinations 0 0
 Agitation/Aggression 1 2
 Depression/Dysphoria 9 1
 Anxiety 4 0
 Euphoria 0 0
 Apathy 0 0
 Disinhibition 0 0
 Irritability 1 0
 Aberrant motor behavior 3 0
 Night-time behavior disturbances 6 0
 Appetite and eating abnormalities 1 1
 NPI severity × frequency  
 total score (max = 144)
25 4
Abbreviations: NPI, Neuropsychiatric Inventory; PIMRA, Psychopathological 
Instrument for Mentally Retarded Adults.
Genome-wide submicroscopic chromosomal analysis 
by 250 k single nucleotide polymorphism array analysis 
(Affymetrix, Inc, Santa Clara, CA) revealed in both 
brothers an identical terminal loss of 2.15 Mb in chromo-
somal region 22q13.32q13.33 (49.03–51.18 Mb according 
to University of California, Santa Cruz genome browser 
Hg 19). Chromosomal analysis in the parents gave normal 
results without any indications for a mosaic pattern (blood 
lymphocytes and buccal cells).
Discussion
In these brothers, with until recently unknown etiology of 
their severe ID and moderate to marked developmental delay 
of speech and language, genome-wide array analysis revealed 
a diagnosis of 22q13 deletion syndrome/Phelan-McDermid 
syndrome, which appeared to be associated with a long-
lasting pattern of unstable mood and behavior. In the absence 
of a family load with (bipolar) affective disorder, in both 
brothers a psychiatric diagnosis of atypical bipolar disorder 
was made, albeit that the youngest patient presented with 
more pronounced symptoms and an onset at earlier age. 
Their respective psychiatric histories disclosed no symptoms 
belonging to the autism spectrum.
Although several authors have suggested that autistic 
symptoms belong to the behavioral phenotype,4,12,16–18,20,21 
the incremental value of such a diagnostic vignette is only 
marginal, given the co-occurrence with severe ID and, as was 
also recently stressed by Sarasua et al7, relies heavily on the 
definition and the validity of the assessment process. In these 
patients, it is not autism that is at the heart of the phenotypical 
presentation but the characteristic combination of marked 
speech and language delay and executive dysfunctions, the 
latter mainly detectable through a pattern of perseverations 
and planning problems.
In retrospect, it can be argued that the fundamental lack of 
expressive language not only intensified the presentation of 
previously observed symptoms of major depression but also 
obscured the fluctuations in mood and behavior typical for 
so-called unstable mood disorder.22 This psychopathological 
syndrome that refers to an atypical bipolar disorder can 
frequently be observed in patients with ID irrespective of the 
etiology.23,24 The dysregulation of affect in these patients is 
most probably related to hypoplasia of the cerebellar vermis 
that is typically involved in the modulation of cognition and 
emotion.25,26
As their symptoms remitted under maintenance therapy 
with a mood stabilizer, compounds from this class may be 
the first choice in the treatment of fluctuating challenging 
behaviors in patients with ID and, more specifically, those 
with 22q13 deletion syndrome in whom an (atypical) bipolar 
disorder may be present. These patients also illustrate that 
categorical diagnoses of autism or ASD should be applied 
with great caution only. Such vignettes may seriously hinder 
the in-depth assessment of an individual patient’s function-
ing following the contextual neuropsychological paradigm.27 
The latter is aimed to understand and to explain functional 
deficits and is relevant for the treatment design.
In conclusion, key elements of the behavioral phenotype 
of the 22q13.3 deletion syndrome, as previously described in 
the literature, are delayed or absent speech and perseverations 
with associated features from the autism spectrum. This is the 
first report of which the data suggest that the psychopatho-
logical phenotype of Phelan-McDermid syndrome comprises 
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oscillating abnormalities in mood and behavior that can be 
attributed to an atypical bipolar disorder.
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